Oral Breakthrough: Septerna's New Pill for Hypoparathyroidism Enters Human Trials

SOUTH SAN FRANCISCO, CA – April 13, 2026 – Septerna, Inc. today announced the start of a Phase 1 clinical trial for SEP-479, a novel, once-daily oral medication for hypoparathyroidism, marking a potentially pivotal shift in treatment for the debilitating rare disease. The move into human testing offers a beacon of hope for thousands of patients currently reliant on burdensome daily injections or a demanding regimen of supplements to manage their condition.

The biotechnology company, which specializes in pioneering drugs for complex G protein-coupled receptors (GPCRs), has dosed the first healthy volunteers in a trial designed to assess the safety and characteristics of the small molecule drug. If successful, SEP-479 could become the first oral therapy that directly mimics the body's missing parathyroid hormone (PTH), fundamentally changing the standard of care.

The Heavy Burden of a Lifelong Condition

Hypoparathyroidism is a rare endocrine disorder where the body produces insufficient PTH, a hormone essential for regulating calcium and phosphate levels. Patients often suffer from a range of persistent and disruptive symptoms, including muscle cramps, chronic fatigue, tingling sensations, and cognitive impairment often described as "brain fog." In severe cases, the condition can lead to life-threatening complications such as cardiac arrhythmias and seizures, while long-term effects include kidney damage and cataracts.

For decades, managing this disease has been a relentless daily struggle. The standard of care involves taking large, frequent doses of calcium and active vitamin D supplements to maintain blood calcium levels. However, this approach is a blunt instrument. Many patients continue to experience debilitating symptoms and sudden, dangerous drops in calcium known as "calcium crashes," which can necessitate emergency medical care. Furthermore, this lifelong regimen carries its own risks, often leading to excess calcium in the urine, kidney stones, and progressive renal failure.

While the recent FDA approval of injectable PTH replacement therapies like Ascendis Pharma's Yorvipath represented a significant step forward, they still require patients to administer daily shots. This reality underscores the profound unmet need for a more convenient, less invasive treatment.

“Hypoparathyroidism is a lifelong condition that patients must manage with either high doses of calcium supplements several times a day or daily parathyroid hormone (PTH) injections, both of which can place a substantial burden on patients over time,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co‑founder of Septerna, in a statement. “We are encouraged by the preclinical data for SEP‑479, which underscore its potential to be a disease modifying therapy for hypoparathyroidism by directly targeting the PTH receptor to provide patients full‑day calcium control and relief from their debilitating symptoms.”

A New Oral Approach: Targeting the Root Cause

Septerna's SEP-479 represents a fundamentally different strategy. It is an oral small molecule designed to directly activate the parathyroid hormone 1 receptor (PTH1R), the same receptor that natural PTH targets. By mimicking the hormone's action, the drug aims to restore the body's natural ability to regulate calcium, potentially eliminating the need for both injections and high-dose supplements.

The company's decision to advance into the clinic is supported by promising preclinical studies. In animal models of hypoparathyroidism, SEP-479 successfully normalized serum calcium levels. In other non-human primate studies, the drug demonstrated the ability to increase serum calcium while reducing the body's own PTH production, a key indicator of its intended pharmacodynamic effect. These studies suggest the potential for a once-daily pill to provide stable, full-day calcium control.

The Phase 1 trial is a randomized, placebo-controlled study that will enroll up to 150 healthy adult participants. It will proceed in two parts: a single-ascending dose (SAD) portion to evaluate safety at escalating doses, followed by a multiple-ascending dose (MAD) portion to assess the effects of once-daily oral dosing over several days. Beyond safety, the trial will closely monitor the drug's pharmacokinetics (how it moves through the body) and pharmacodynamics, measuring changes in calcium and other key biomarkers. Septerna anticipates reporting initial data from this crucial trial in late 2026 or early 2027.

The Science Behind the Pill: A Test for a Novel Platform

The development of an oral drug for a target as complex as the PTH1R is a significant scientific challenge and a major test for Septerna's proprietary technology. GPCRs are a vast family of receptors embedded in cell membranes that act as gatekeepers for cellular communication, making them prime targets for therapeutics. However, their complex structures have historically made it difficult to design effective and selective oral small molecules, with many treatments resorting to injectable biologics.

Septerna was founded to overcome this barrier with its Native Complex Platform®. This technology is designed to stabilize GPCRs in their natural, functional state, allowing researchers to identify novel small molecules that can precisely modulate their activity. The platform's success is predicated on its ability to unlock new therapeutic possibilities for a wide range of diseases.

SEP-479 is the first clinical-stage candidate to emerge from this platform, making its journey through the clinic a critical validation of the company's entire scientific approach. Success would not only be a landmark achievement for hypoparathyroidism treatment but would also signal the platform's potential to generate a pipeline of innovative oral drugs for other challenging diseases in endocrinology, immunology, and metabolic disorders.

Navigating the Rare Disease Market

The initiation of this trial is also a strategic move within the competitive landscape of rare diseases. While hypoparathyroidism affects an estimated 77,000 people in the United States, the chronic nature of the disease and the high dissatisfaction with current treatments create a significant market opportunity for a superior therapy. Orphan drugs for rare conditions often command premium pricing due to the high unmet need and the cost of development for smaller patient populations.

By pursuing an oral therapy, Septerna is directly addressing the primary drawback of existing and recently approved PTH replacement therapies: the need for daily injections. The convenience of a once-daily pill could make SEP-479 a highly attractive option for both patients and clinicians, potentially positioning it as a future market leader if clinical data proves positive. The significant economic burden of hypoparathyroidism on the healthcare system, driven by frequent hospitalizations and complications, further strengthens the case for a novel therapy that offers better disease control and quality of life.

As SEP-479 begins its clinical journey, the eyes of patients, physicians, and investors will be watching closely. The path through clinical development is long and uncertain, but for a community long awaiting a simpler and more effective way to manage their condition, this trial represents a tangible step toward a new era of treatment.